<!DOCTYPE html>
<html lang="en-us">
  <head>
    <meta charset="utf-8">
    <link href="https://fonts.googleapis.com/icon?family=Material+Icons" rel="stylesheet"> 
    <link rel="stylesheet" href="https://use.fontawesome.com/releases/v5.6.3/css/all.css" integrity="sha384-UHRtZLI+pbxtHCWp1t77Bi1L4ZtiqrqD80Kn4Z8NTSRyMA2Fd33n5dQ8lWUE00s/" crossorigin="anonymous">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/4.7.0/css/font-awesome.min.css"> 
    
    <link rel="stylesheet" href="../../../fonts/academicons-1.8.6/css/academicons.min.css"/>
    <link rel="icon" type="image/png" sizes="32x32" href="../../../logo/bodhi.png"> 
    <meta name="viewport" content="width=device-width, initial-scale=1">
    
    
    
    <title>APOBEC3B and APOBEC mutational signature as potential predictive markers for immunotherapy response in non-small cell lung cancer - 王诗翔</title>
    
     
    <meta property="og:title" content="APOBEC3B and APOBEC mutational signature as potential predictive markers for immunotherapy response in non-small cell lung cancer - Shixiang Wang | 王诗翔">
    

    
      
    

    

    
    

    <link rel="stylesheet" href="../../../css/style.css" />
    <link rel="stylesheet" href="../../../css/mystyle.css" /> 
    <link rel="stylesheet" href="../../../css/fonts.css" />
    
<script async src="../../../js/load-typekit.js"></script>


<link rel="stylesheet" href="../../../css/custom.css" />

  </head>

  
  <body class="cn">
    <header class="masthead">
      

<h1><a href="../../../logo/ShixiangWang.png"><img src="../../../logo/ShixiangWang.png" alt="Shixiang Wang" /></a></h1>



      <nav class="menu">
        <input id="menu-check" type="checkbox" />
        <label id="menu-label" for="menu-check" class="unselectable">
          <span class="icon close-icon">✕</span>
          <span class="icon open-icon">☰</span>
          <span class="text">Menu</span>
        </label>
        <ul>
        
        
        <li><a href="../../../">首页</a></li>
        
        <li><a href="../../../cn/about/">关于</a></li>
        
        <li><a href="../../../cn/post/">博客</a></li>
        
        <li><a href="../../../cn/read/">读书</a></li>
        
        <li><a href="../../../cn/writing">写作</a></li>
        
        <li><a href="../../../cn/research/">研究</a></li>
        
        <li><a href="../../../cn/tools/">工具</a></li>
        
        <li><a href="../../../cn/cv-cn/shixiang">简历</a></li>
        
        <li><a href="../../../logo/qrcode.jpg">公众号</a></li>
        
        <li><a href="https://www.jianshu.com/u/b6608e27dc74">简书</a></li>
        
        <li><a href="../../../cn/todo">ToDo</a></li>
        
        <li><a href="../../../en/">English</a></li>
        
        

<li class="menu-extra"></li>



<li><a href="https://github.com/ShixiangWang/home/edit/master/content/cn/research/apobec3b_signature.md" target="_blank">编辑</a></li>


<li><a href="../../../cn/index.xml" type="application/rss+xml" title="RSS feed">订阅</a></li>

<li><a href="http://creativecommons.org/licenses/by-nc-sa/4.0/" title="Attribution-NonCommercial-ShareAlike 4.0 International">版权</a></li>


        </ul>
      </nav>
    </header>

    <article class="main">
      <header class="title">
        

<h1>APOBEC3B and APOBEC mutational signature as potential predictive markers for immunotherapy response in non-small cell lung cancer</h1>



<h3>王诗翔 &middot 
2019-06-20</h3> 


   
  


      </header>


<p>主要发现：APOBEC mutational signature 在 NSCLC 免疫治疗反应组内特异性富集。</p>
<h2 id="摘要">摘要</h2>
<p>Non-small cell lung cancer (NSCLC) is known to carry heavy mutation load. Besides smoking, cytidine deaminase APOBEC3B plays a key role in the mutation process of NSCLC. APOBEC3B is also reported to be upregulated and predicts bad prognosis in NSCLC. However, targeting APOBEC3B high NSCLC is still a big challenge. Here we show that APOBEC3B upregulation is significantly associated with immune gene expression, and APOBEC3B expression positively correlates with known immunotherapy response biomarkers, including: PD-L1 expression and T-cell infiltration in NSCLC. Importantly, APOBEC mutational signature is specifically enriched in NSCLC patients with durable clinical benefit after immunotherapy and APOBEC mutation count can be better than total mutation in predicting immunotherapy response. In together, this work provides evidence that APOBEC3B upregulation and APOBEC mutation count can be used as novel predictive markers in guiding NSCLC checkpoint blockade immunotherapy.</p>
<h2 id="全文">全文</h2>
<p><a href="https://www.nature.com/articles/s41388-018-0245-9.pdf?origin=ppub">点击阅读</a></p>


  <footer>
  
<nav class="post-nav">
  <span class="nav-prev">&larr; <a href="../../../cn/research/tmb_diff_in_sex/">The predictive power of tumor mutational burden in lung cancer immunotherapy response is influenced by patients’ sex</a></span>
  <span class="nav-next"></span>
</nav>
<script type="text/javascript">
document.addEventListener('keyup', function(e) {
  if (e.target.nodeName.toUpperCase() != 'BODY') return;
  var url = false;
  if (e.which == 37) {  
    
    url = '\/cn\/research\/tmb_diff_in_sex\/';
    
  } else if (e.which == 39) {  
    
  }
  if (url) window.location = url;
});
</script>



<section class="comments">
  <div id="disqus_thread"></div>
  <script src="../../../js/disqusloader.min.js"></script>
  <script>
  var disqus_config = function () {
  
    this.page.url = "https:\/\/shixiangwang.github.io\/home\/" + location.pathname;
  
  };
  (function() {
    var inIFrame = function() {
      var iframe = true;
      try { iframe = window.self !== window.top; } catch (e) {}
      return iframe;
    };
    if (inIFrame()) return;
    var disqus_js = '//home-xjdzylqrzp.disqus.com/embed.js';
    
    if (location.hash.match(/^#comment/)) {
      var d = document, s = d.createElement('script');
      s.src = disqus_js; s.async = true;
      s.setAttribute('data-timestamp', +new Date());
      (d.head || d.body).appendChild(s);
    } else {
      disqusLoader('#disqus_thread', {
        scriptUrl: disqus_js, laziness: 0, disqusConfig: disqus_config
      });
    }
  })();
  </script>
  <noscript>Please enable JavaScript to view the <a href="https://disqus.com/?ref_noscript">comments powered by Disqus.</a></noscript>
</section>




<script async src="../../../js/fix-toc.js"></script>

<script async src="../../../js/center-img.js"></script>

<script async src="../../../js/right-quote.js"></script>

<script async src="../../../js/no-highlight.js"></script>

<script async src="../../../js/fix-footnote.js"></script>

<script async src="../../../js/math-code.js"></script>

<script async src="../../../js/external-link.js"></script>

<script async src="../../../js/alt-title.js"></script>

<script async src="../../../js/header-link.js"></script>


<script async src="//cdn.bootcss.com/mathjax/2.7.5/MathJax.js?config=TeX-MML-AM_CHTML"></script>

  


  
  
  

  <div class="copyright"><a href="mailto:w_shixiang@163.com"><!-- raw HTML omitted --><!-- raw HTML omitted --></a> · <a href="https://github.com/ShixiangWang"><!-- raw HTML omitted --><!-- raw HTML omitted --></a> · <a href="https://stackoverflow.com/users/7662327/shixiang-wang"><!-- raw HTML omitted --><!-- raw HTML omitted --></a> · <a href="https://scholar.google.com/citations?user=FvNp0NkAAAAJ&amp;hl=zh-CN"><!-- raw HTML omitted --><!-- raw HTML omitted --></a> · <a href="https://orcid.org/0000-0001-9855-7357"><!-- raw HTML omitted --><!-- raw HTML omitted --></a> · <a href="https://www.researchgate.net/profile/Wang_Shixiang4"><!-- raw HTML omitted --><!-- raw HTML omitted --></a> <!-- raw HTML omitted --> 本站由 <a href="https://gohugo.io">Hugo</a> 和 <a href="https://bookdown.org/yihui/blogdown/">Blogdown</a> 强力驱动 © <a href="../../../">王诗翔</a> 2017 - 2020 </div>
  
  

  <script type="text/javascript" src="//rf.revolvermaps.com/0/0/6.js?i=56h9es09xn7&amp;m=6&amp;c=ff0000&amp;cr1=ffffff&amp;f=arial&amp;l=1" async="async"></script>
  </footer>
  </article>
  
  </body>
</html>

